8-K filing — X4 Pharmaceuticals, Inc (XFOR)
Filed: 2026-09-08 AccNo: 0001501697-26-000072 Size: 158 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
X4 Pharmaceuticals shares are trading lower. The company announced the FDA’s agreement to reduce the 4WARD Phase 3 trial sample size. Enrollment is expected to finish by year-end 2026, with topline data in H1 2028.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
X4 Pharmaceuticals Says FDA Agreed To Reduce Phase 3 4WARD Chronic Neutropenia Trial Size From 176 To 126 Participants; Expects Enrollment Completion By Year-End 2026, Topline Data In H1 2028
FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=919722